Table 5. Treatment options iMCD-NOS and... | American Society of Hematology

Table 5.

Treatment options

iMCD-NOS and iMCD-TAFRO	POEMS-associated MCD	HHV8-MCD
First-line therapy
• Siltuximab	• If no bone lesions, iMCD-like therapy	• If HIV-positive, combination antiretroviral therapy
• Tocilizumab	• If bone lesions, myeloma type therapy including ASCT	• Rituximab
• Corticosteroids
Second line and beyond options
• Rituximab	As above	• Etoposide
• Cyclosporin*		• Liposomal doxorubicin
• Sirolimus*		• Interferon
• IVIG*		• Antiviral therapy
• Thalidomide*
• Lenalidomide*
• Bortezomib
• R-CVP,† R-CHOP†
• ASCT†

iMCD-NOS and iMCD-TAFRO	POEMS-associated MCD	HHV8-MCD
First-line therapy
• Siltuximab	• If no bone lesions, iMCD-like therapy	• If HIV-positive, combination antiretroviral therapy
• Tocilizumab	• If bone lesions, myeloma type therapy including ASCT	• Rituximab
• Corticosteroids
Second line and beyond options
• Rituximab	As above	• Etoposide
• Cyclosporin*		• Liposomal doxorubicin
• Sirolimus*		• Interferon
• IVIG*		• Antiviral therapy
• Thalidomide*
• Lenalidomide*
• Bortezomib
• R-CVP,† R-CHOP†
• ASCT†

IVIG, IV immunoglobulin; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CVP, rituximab, cyclophosphamide, vincristine, prednisone.

Immunomodulatory therapies.

Combination chemotherapies.